Characteristics of patients with axial spondyloarthritis included in this study and for all patients in DESIR cohort
| Patients included in this study | DESIR cohort | |||||
|---|---|---|---|---|---|---|
| Total n=167 | Males n=83 (50%) | Females n=84 (50%) | Total (n=486) | Males n=244 (50%) | Females n=242 (50%) | |
| Age (years) | 33.0±9.0 | 31.4±8.4 | 34.6±9.4 | 33.0±8.6 | 31.8±8.4 | 34.1±8.7 |
| Male | 83 (50) | 238 (50) | ||||
| Fulfilling ASAS criteria | ||||||
| Imaging arm only | 32 (19) | 13 (16) | 19 (23) | 81 (17) | 34 (14) | 47 (19) |
| Clinical arm only | 59 (35) | 23 (28) | 36 (43) | 201 (41) | 78 (32) | 123 (51) |
| Both arms | 76 (46) | 47 (57) | 29 (34) | 204 (42) | 132 (54) | 72 (30) |
| Back pain duration (months) | 17.8±10.8 | 16.2±9.5 | 19.4±11.8 | 18.0±10.6 | 17.6±10.4 | 18.5±10.9 |
| HLA-B27 positive | 136 (81) | 71 (86) | 65 (74) | 406 (83) | 210 (86) | 196 (81) |
| ASDAS (range) | 2.6 (0.6–5.5) | 2.5 (0.7–5.5) | 2.6 (0.6–5.2) | 2.6 (0–5–6.1) | 2.5 (0–5–6.1) | 2.6 (0.6–5.2) |
| BASDAI (0–10) (range) | 4.3 (0.2–9.8) | 4.1 (0.2–7.9) | 4.5 (0.2–9.8) | 4.3 (0–9.8) | 3.9 (0–9.7) | 4.6 (0.2–9.8) |
| BASFI (0–10) | 2.9±2.3 | 2.6±2.1 | 3.1±2.5 | 3.0±2.3 | 2.7±2.1 | 3.3±2.3 |
| Night pain (0–10) (range) | 4.3 (0–10) | 3.9 (0–10) | 4.8 (0–10) | 4.5 (0–10) | 4.1 (0–10) | 4.9 (0–10) |
| Patient's global (0–10) (range) | 4.8 (0–10) | 4.6 (0–10) | 5.0 (0–10) | 4.9 (0–10) | 4.5 (0–10) | 5.3 (0–10) |
| ESR (mm/h) (range) | 15.5 (1–76)) | 14.7 (1–73) | 16.3 (2–76) | 14.9 (1–124) | 14.1 (1–76) | 15.8 (1–124) |
| CRP (mg/L) (range) | 9.1 (0.1–88) | 11.4 (0.3–88) | 7.0 (0.1–67) | 9.0 (0.1–91) | 11.1 (0.3–91) | 6.8 (0.1–74) |
| Elevated CRP | 48 (30) | 26 (33) | 22 (26) | 162 (35) | 89 (39) | 73 (31) |
| ASQoL (0–18) | 8.9±5.1 | 7.7±5.0 | 10.0±4.9 | 9.0±5.0 | 7.9.±5.0 | 10.2±4.8 |
| Treatment (baseline) | ||||||
| NSAID | 162 (97) | 79 (95) | 83 (99) | 460 (95) | 232 (95) | 228 (94) |
| Anti-TNF-α | 0 | 0 | 0 | 0 | 0 | 0 |
| Treatment (at 24 months) | ||||||
| NSAID | 112 (67) | 52 (63) | 60 (71) | 278 (57) | 129 (53) | 149 (62) |
| Anti-TNF-α | 58 (35) | 30 (36) | 27 (32) | 130 (27) | 62 (25) | 67 (28) |
| SPARCC (0–72) (range) | 5.6 (0–42) | 8.8 (0–42) | 2.4 (0–23) | 5.1 (0–55) | 7.7 (0–55) | 2.5 (0–26) |
| Positive MRI | NA | NA | NA | |||
| MRI-positive/MRI- positive* | 49 (29) | 30 (36.5) | 19 (23) | |||
| MRI-positive/MRI-negative | 23 (14) | 17 (21) | 6 (7) | |||
| MRI-negative/MRI-positive | 11 (7) | 5 (6) | 6 (7) | |||
| MRI-negative/MRI-negative | 82 (50) | 30 (36.5) | 52 (63) | |||
Unless otherwise specified, table shows mean±SD or absolute number (percentage) for all patients included in this analysis and the entire cohort. Furthermore, the results are also stratified by gender.
*Baseline/12 months.
Anti-TNF, antitumor necrosis factor alpha therapy; ASAS, Assessment of SpondyloArthritis international Society; ASDAS, Ankylosing Spondylitis Disease Activity Index; ASQoL, Ankylosing Spondylitis Quality of Life; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; CRP, C reactive protein; DESIR, DEvenir des Spondylarthopathies Indifférenciées Récentes; ESR, erythrocyte sedimentation rate; HLA-B27, human leucocyte antigen B27; MRI-SIJ, sacroiliac joint MRI; NSAIDs, non-steroidal anti-inflammatory drugs; Patient's global, patient’s global assessment for disease activity; SPARCC, Spondyloarthritis Research Consortium of Canada scoring system.